Literature DB >> 25943200

Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.

Daisuke Tamura1, Roberta L DeBiasi2, Margaret Okomo-Adhiambo1, Vasiliy P Mishin1, Angela P Campbell1, Brett Loechelt3, Bernhard L Wiedermann4, Alicia M Fry1, Larisa V Gubareva1.   

Abstract

Prolonged treatment of an immunocompromised child with oseltamivir and zanamivir for A(H1N1)pdm09 virus infection led to the emergence of viruses carrying H275Y and/or E119G in the neuraminidase (NA). When phenotypically evaluated by NA inhibition, the dual H275Y-E119G substitution caused highly reduced inhibition by 4 NA inhibitors: oseltamivir, zanamivir, peramivir, and laninamivir. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  drug resistance; neuraminidase; oseltamivir; pyrosequencing; zanamivir

Mesh：

Substances：

Year:  2015        PMID： 25943200     DOI： 10.1093/infdis/jiv245

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


  19 in total

1.  Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.

Authors:  Maki Kiso; Tiago J S Lopes; Seiya Yamayoshi; Mutsumi Ito; Makoto Yamashita; Noriko Nakajima; Hideki Hasegawa; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2018-03-05       Impact factor: 5.226

2.  Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.

Authors:  Timothy M Uyeki; Henry H Bernstein; John S Bradley; Janet A Englund; Thomas M File; Alicia M Fry; Stefan Gravenstein; Frederick G Hayden; Scott A Harper; Jon Mark Hirshon; Michael G Ison; B Lynn Johnston; Shandra L Knight; Allison McGeer; Laura E Riley; Cameron R Wolfe; Paul E Alexander; Andrew T Pavia
Journal:  Clin Infect Dis       Date:  2019-03-05       Impact factor: 9.079

3.  Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model.

Authors:  Philippe Noriel Q Pascua; Bindumadhav M Marathe; Peter Vogel; Richard J Webby; Elena A Govorkova
Journal:  J Antimicrob Chemother       Date:  2019-05-01       Impact factor: 5.790

4.  Anti-influenza effect and action mechanisms of the chemical constituent gallocatechin-7-gallate from Pithecellobium clypearia Benth.

Authors:  Chao Li; Lv-Jie Xu; Wen-Wen Lian; Xiao-Cong Pang; Hao Jia; Ai-Lin Liu; Guan-Hua Du
Journal:  Acta Pharmacol Sin       Date:  2018-05-25       Impact factor: 6.150

Review 5.  How I treat respiratory viral infections in the setting of intensive chemotherapy or hematopoietic cell transplantation.

Authors:  Alpana Waghmare; Janet A Englund; Michael Boeckh
Journal:  Blood       Date:  2016-03-11       Impact factor: 22.113

6.  Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART.

Authors:  Larisa V Gubareva; Eric Fallows; Vasiliy P Mishin; Erin Hodges; Abdullah Brooks; John Barnes; Alicia M Fry; William Kramp; Roxanne Shively; David E Wentworth; Kristin Weidemaier; Ross Jacobson
Journal:  Euro Surveill       Date:  2017-05-04

7.  Laninamivir-Interferon Lambda 1 Combination Treatment Promotes Resistance by Influenza A Virus More Rapidly than Laninamivir Alone.

Authors:  Simone E Adams; Vladimir Y Lugovtsev; Anastasia Kan; Nicolai V Bovin; Raymond P Donnelly; Natalia A Ilyushina
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

Review 8.  Clinical Implications of Antiviral Resistance in Influenza.

Authors:  Timothy C M Li; Martin C W Chan; Nelson Lee
Journal:  Viruses       Date:  2015-09-14       Impact factor: 5.048

Review 9.  A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir.

Authors:  Yacine Abed; Guy Boivin
Journal:  Open Forum Infect Dis       Date:  2017-05-18       Impact factor: 3.835

10.  Screening of neuraminidase inhibitory activities of some medicinal plants traditionally used in Lingnan Chinese medicines.

Authors:  Jiawei Liu; Mian Zu; Kaotan Chen; Li Gao; Huan Min; Weiling Zhuo; Weiwen Chen; Ailin Liu
Journal:  BMC Complement Altern Med       Date:  2018-03-20       Impact factor: 3.659
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.